STAT+: Gilead sours on the ‘don’t eat me’ business
Gilead will no longer develop magrolimab, a treatment targeting the “don’t eat me signal” exploited by tumors in blood cancer after another clinical setback that makes its $5 billion investment in…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.
The need-to-know this morning
- AstraZeneca reported fourth quarter and 2023 earnings.
- BioNTech and Autolus announced a CAR-T cell therapy partnership.
- Kyverna Therapeutics, a developer of cell therapies for autoimmune diseases, priced its IPO at $22 per share, raising $319 million.
- The Phase 3 study of resmetirom, a treatment for MASH made by Madrigal Pharmaceuticals, was published in the New England Journal of Medicine.
Pharma returns to Washington
Sen. Bernie Sanders, who all but séanced Frederick Banting to scold the CEO of Eli Lilly and tried to sell Moderna’s Stéphane Bancel on nationalizing pharmaceutical research, will again play haranguing host to drug industry executives.
What's Your Reaction?
